ST. PAUL, Minn.--(BUSINESS WIRE)--Spineology Inc., the innovator in anatomy conserving surgery technologies, today announced that it has entered into an agreement with BioDlogics to distribute that company’s line of allograft tissue forms.
“BioDlogics’ products provide a very attractive complement to our current product line,” said John Booth, CEO for Spineology. “We believe that recent advances in regenerative medicine have the potential to significantly improve patient outcomes in numerous clinical applications. We look forward to working with BioDlogics to offer its line of novel allograft tissue to surgeons using our products.”
“Spineology’s corporate focus on minimally invasive surgical techniques coupled with its growing direct sales force provides an attractive opportunity for us to expand our penetration in a growing market segment,” said Greg Brophy, president of BioDlogics. “We are excited to work with Spineology as a distribution partner.”
About Spineology Inc.
Spineology Inc., the innovator in
anatomy-conserving spine surgery, develops spinal implants and
instruments. Spineology surgical techniques conserve spinal bone,
ligament and muscle tissue. Spineology is committed to increasing
procedural efficiency, reducing surgical morbidity and accelerating
patient recovery. Learn more at spineology.com.
About BioDlogics, LLC
BioDlogics, LLC, is a biomedical
company formed in 2005 to engage in the development and
commercialization of novel wound covering products derived from amniotic
tissue. Its research and development efforts are focused on the
regenerative potential of amniotic tissue given its unique biologic
structure, its rich source of proteins, growth factors and
undifferentiated stem cells, and the unique immune privilege that
characterizes its function in the body. From the recovery of tissue from
live, healthy donors during childbirth to the development of new
products that will improve patient outcomes, BioDlogics is committed to
unlocking the regenerative potential of the human body.